Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Seeking Alpha9h
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Modern Healthcare3h
Hims & Hers defends compounded GLP-1s as shortages wane
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Hims & Hers to stop reporting on orders, average order value after 2024
Says trajectory in 2024 “nothing short of phenomenal.” Says business trajectory setting “robust foundation” for 2025.
Hims & Hers Health plans to offer generic version of Novo Nordisk's drug
Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...
Hims & Hers Health Raises Outlook, Swings to 3Q Profit
Hims & Hers Health raised its full-year outlook after it swung to a profit in the third quarter boosted by a tax benefit and consumer demand for weight-loss drugs.
Palantir, Trump Media, Hims & Hers Health, NXP Semiconductors, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow ...
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News
Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's ...
Investor's Business Daily on MSN14h
IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory
Hims stock jumped late Monday after the online pharmacy beat expectations, helped by Hims & Hers' weight-loss drug.